Core Viewpoint - Meikang Bio (300439.SZ) announced that its subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., has obtained the Medical Device Registration Certificate for in vitro diagnostic reagents from the Jiangxi Provincial Drug Administration, enhancing its product line in the field of chemiluminescence immunoassay [1] Group 1 - The newly acquired registration certificate pertains to the "Heparin-Binding Protein Detection Kit (Chemiluminescence Immunoassay Method)" [1] - This achievement enriches the company's product offerings in the niche market of in vitro diagnostic chemiluminescence [1] - The development is expected to enhance the company's core competitiveness and market expansion capabilities, positively impacting future operations [1]

Core Viewpoint - Meikang Bio (300439.SZ) announced that its subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., has obtained the Medical Device Registration Certificate for in vitro diagnostic reagents from the Jiangxi Provincial Drug Administration, specifically for the "Heparin-Binding Protein Test Kit (Chemiluminescent Immunoassay)" [1] Group 1 - The acquisition of the registration certificate enhances the product line in the niche market of in vitro diagnostic chemiluminescence [1] - This development is expected to strengthen the company's core competitiveness and market expansion capabilities [1] - The positive impact on the company's future operations is anticipated as a result of this certification [1]

人民财讯11月11日电，美康生物（300439）11月11日公告，近日，公司控股子公司江西美康盛德生物科 技有限公司取得由江西省药监局颁发的《医疗器械注册证(体外诊断试剂)》。产品名称为肝素结合蛋白 检测试剂盒(化学发光免疫分析法)，用于体外定量测定人血浆肝素结合蛋白(HBP)的浓度。临床上可作 为炎症的辅助指标。 ...